Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
Abstract Introduction To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3 DISCOVER-2 clinical trial. Methods Adult patients w...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-02-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-024-00642-9 |
| _version_ | 1827321271415734272 |
|---|---|
| author | Jeffrey R. Curtis Iain B. McInnes Proton Rahman Dafna D. Gladman Steven Peterson Feifei Yang Oluwakayode Adejoro Alexa P. Kollmeier Natalie J. Shiff Chenglong Han May Shawi William Tillett Philip J. Mease |
| author_facet | Jeffrey R. Curtis Iain B. McInnes Proton Rahman Dafna D. Gladman Steven Peterson Feifei Yang Oluwakayode Adejoro Alexa P. Kollmeier Natalie J. Shiff Chenglong Han May Shawi William Tillett Philip J. Mease |
| author_sort | Jeffrey R. Curtis |
| collection | DOAJ |
| description | Abstract Introduction To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3 DISCOVER-2 clinical trial. Methods Adult patients with PsA were randomized to subcutaneous injections of guselkumab 100 mg every 4 weeks (Q4W); at weeks 0, 4, then every 8 weeks (Q8W); or placebo (through week 24 with crossover to guselkumab Q4W). Work productivity and nonwork daily activity impairment were assessed using the Work Productivity and Activity Impairment Questionnaire for PsA (WPAI-PsA) and patient-reported general health status using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index and EQ-Visual Analog Scale (EQ-VAS). Least-squares (LS) mean changes from baseline in WPAI-PsA domains and EQ-5D-5L/EQ-VAS were assessed through week 100. Changes in employment status were utilized to estimate potential indirect savings from improved work productivity. Results Of 739 randomized patients, 738 had available baseline data for the analyses (Q4W 245; Q8W 248; placebo 245). At week 24, greater improvements in work productivity, nonwork daily activity, and EQ-5D-5L/EQ-VAS were observed in the Q4W and Q8W groups versus the placebo group. At week 100, LS mean reductions in work productivity impairment (− 23.8% to − 28.0%) and nonwork daily activity impairment (– 26.6% to − 29.2%) and improvements in EQ-5D-5L/EQ-VAS (0.14 to 0.15/21.2 to 25.0) were maintained in patients receiving guselkumab. Among patients employed at baseline, 12.1–16.4% were not employed at week 100, and 20.0–25.3% shifted from not employed at baseline to employed at week 100. Potential yearly indirect cost savings (USD) from improved work productivity at week 100 ranged from $16,529 to $19,409. Conclusion Patients with active PsA treated with guselkumab demonstrated reduced impairment in work productivity and nonwork daily activity, together with improvement in general health status and substantial potential cost savings, over a 2-year period. Trial Registration Clinicaltrials.gov identifier: NCT03158285. |
| first_indexed | 2024-04-25T01:03:26Z |
| format | Article |
| id | doaj.art-0fe4fa79267340eca6264c7603694203 |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-04-25T01:03:26Z |
| publishDate | 2024-02-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-0fe4fa79267340eca6264c76036942032024-03-10T12:21:49ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842024-02-0111242544110.1007/s40744-024-00642-9Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic ArthritisJeffrey R. Curtis0Iain B. McInnes1Proton Rahman2Dafna D. Gladman3Steven Peterson4Feifei Yang5Oluwakayode Adejoro6Alexa P. Kollmeier7Natalie J. Shiff8Chenglong Han9May Shawi10William Tillett11Philip J. Mease12Division of Clinical Immunology and Rheumatology, Department of Medicine, Immunology and Rheumatology, University of Alabama at BirminghamCollege of Medical Veterinary and Life Sciences, University of GlasgowFaculty of Medicine, Division of Rheumatology, Memorial University of NewfoundlandDepartment of Medicine, University of TorontoDepartment of Immunology, Janssen Global Services, LLCDepartment of Immunology, Janssen Global Services, LLCDepartment of Immunology, Janssen Global Services, LLCDepartment of Immunology, Janssen Research & Development, LLCJanssen Scientific Affairs, LLCPatient-Reported Outcomes, Janssen Global Services, LLCJanssen Research & Development, LLCDepartment of Life Sciences, Centre for Therapeutic Innovation, Royal National Hospital for Rheumatic DiseasesRheumatology Research, Providence Swedish Medical CenterAbstract Introduction To evaluate the effect of guselkumab on work productivity and nonwork daily activity impairment and general health status through 2 years in patients who were biologic-naïve with active psoriatic arthritis (PsA) in the phase 3 DISCOVER-2 clinical trial. Methods Adult patients with PsA were randomized to subcutaneous injections of guselkumab 100 mg every 4 weeks (Q4W); at weeks 0, 4, then every 8 weeks (Q8W); or placebo (through week 24 with crossover to guselkumab Q4W). Work productivity and nonwork daily activity impairment were assessed using the Work Productivity and Activity Impairment Questionnaire for PsA (WPAI-PsA) and patient-reported general health status using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index and EQ-Visual Analog Scale (EQ-VAS). Least-squares (LS) mean changes from baseline in WPAI-PsA domains and EQ-5D-5L/EQ-VAS were assessed through week 100. Changes in employment status were utilized to estimate potential indirect savings from improved work productivity. Results Of 739 randomized patients, 738 had available baseline data for the analyses (Q4W 245; Q8W 248; placebo 245). At week 24, greater improvements in work productivity, nonwork daily activity, and EQ-5D-5L/EQ-VAS were observed in the Q4W and Q8W groups versus the placebo group. At week 100, LS mean reductions in work productivity impairment (− 23.8% to − 28.0%) and nonwork daily activity impairment (– 26.6% to − 29.2%) and improvements in EQ-5D-5L/EQ-VAS (0.14 to 0.15/21.2 to 25.0) were maintained in patients receiving guselkumab. Among patients employed at baseline, 12.1–16.4% were not employed at week 100, and 20.0–25.3% shifted from not employed at baseline to employed at week 100. Potential yearly indirect cost savings (USD) from improved work productivity at week 100 ranged from $16,529 to $19,409. Conclusion Patients with active PsA treated with guselkumab demonstrated reduced impairment in work productivity and nonwork daily activity, together with improvement in general health status and substantial potential cost savings, over a 2-year period. Trial Registration Clinicaltrials.gov identifier: NCT03158285.https://doi.org/10.1007/s40744-024-00642-9GuselkumabPsoriatic arthritisWork productivityHealth-related quality of life |
| spellingShingle | Jeffrey R. Curtis Iain B. McInnes Proton Rahman Dafna D. Gladman Steven Peterson Feifei Yang Oluwakayode Adejoro Alexa P. Kollmeier Natalie J. Shiff Chenglong Han May Shawi William Tillett Philip J. Mease Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis Rheumatology and Therapy Guselkumab Psoriatic arthritis Work productivity Health-related quality of life |
| title | Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis |
| title_full | Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis |
| title_fullStr | Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis |
| title_full_unstemmed | Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis |
| title_short | Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis |
| title_sort | work productivity and general health through 2 years of guselkumab treatment in a phase 3 randomized trial of patients with active psoriatic arthritis |
| topic | Guselkumab Psoriatic arthritis Work productivity Health-related quality of life |
| url | https://doi.org/10.1007/s40744-024-00642-9 |
| work_keys_str_mv | AT jeffreyrcurtis workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT iainbmcinnes workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT protonrahman workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT dafnadgladman workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT stevenpeterson workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT feifeiyang workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT oluwakayodeadejoro workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT alexapkollmeier workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT nataliejshiff workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT chenglonghan workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT mayshawi workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT williamtillett workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis AT philipjmease workproductivityandgeneralhealththrough2yearsofguselkumabtreatmentinaphase3randomizedtrialofpatientswithactivepsoriaticarthritis |